Molecular Dx Reimbursement: Medicare Contractor Seeks Tighter Controls

West Coast contractor Palmetto issues draft proposal establishing a"non-coverage" policy for molecular tests not explicitly covered by Palmetto or a national CMS directive.

More from Archive

More from Pink Sheet